Pfizer And BioNTech Announced Topline Results From An Ongoing Phase 3 Trial Cohort Evaluating 30-µg Dose Of LP.8.1-adapted Monovalent Comirnaty 2025-2026 Formula, Demonstrating Robust Immune Response In Older Patients
Author: Benzinga Newsdesk | September 08, 2025 06:48am
Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the LP.8.1-adapted COVID-19 vaccine 2025-2026 Formula
First LP.8.1 sublineage clinical findings reinforce pre-clinical data supporting recent FDA approval of 2025-2026 Formula of Pfizer-BioNTech COVID-19 Vaccine